Friendly bacteria reduce hospital infections

Nov 06, 2008

A probiotic bacterium, Lactobacillus plantarum 299, has been used to out-compete the dangerous bacteria that cause respiratory illness in ventilated patients. Research published in BioMed Central's open access journal Critical Care describes how applying a bacterial solution in place of normal antiseptics is effective in preventing the most common cause of ventilator-associated pneumonia (VAP).

Bengt Klarin from the University Hospital in Lund, Sweden, led a team of researchers who carried out a randomised, controlled trial in fifty patients, comparing friendly bacteria to the normally used antiseptic chlorhexidine (CHX). Klarin said, "We hypothesised that swabbing the mouth with probiotics would be an effective (and microbiologically attractive) method of reducing pathogenic oral microorganisms in intubated, mechanically ventilated, critically ill patients."

VAP is a common complication in patients on breathing machines. It occurs when harmful bacteria from the mouth, throat or breathing tube are inhaled into the lungs. Because most people on ventilation are sedated or unable to communicate, initial symptoms of pneumonia can be difficult to spot. According to Klarin, "VAP is connected with longer intensive care and hospital stays, additional costs and high mortality. The risk of developing this condition increases by 1% with each additional day of mechanical ventilation."

The authors found that the probiotic treatment was as effective as the antiseptic. Use of the bacteria has other advantages; there are common side effects associated with CHX use in oral care, including tooth discoloration, irritation and, very occasionally, serious allergic reactions. Moreover, CHX diluted by saliva and represents an additional risk for the creation of resistant strains. The authors claim that the L. plantarum 299 solves these problems, "It is not likely to incorporate resistance genes or plasmids or to transfer genetic material. Consequently it does not contribute to the development of antibiotic-resistant strains. As the bacteria adhere to the oral mucosa, they are able to counteract potentially pathogenic bacteria around the clock, which is superior to the fairly short-term effect of orally applied chemical agents."

L. plantarum is normally present in saliva and is also commonly found in fermented food products like pickles and sauerkraut. The authors found no negative side effects of using it in this study.

Citation: Use of the probiotic Lactobacillus plantarum 299 to reduce pathogenic bacteria in the oropharynx of intubated patients: a randomised controlled open pilot study
Bengt Klarin, Göran Molin, Bengt Jeppsson and Anders Larsson, Critical Care (in press)
ccforum.com/

Source: BioMed Central

Explore further: US scientists make embryonic stem cells from adult skin

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Leeches help save woman's ear after pit bull mauling

Apr 18, 2014

(HealthDay)—A pit bull attack in July 2013 left a 19-year-old woman with her left ear ripped from her head, leaving an open wound. After preserving the ear, the surgical team started with a reconnection ...

New pain relief targets discovered

Apr 17, 2014

Scientists have identified new pain relief targets that could be used to provide relief from chemotherapy-induced pain. BBSRC-funded researchers at King's College London made the discovery when researching ...

User comments : 0

More news stories

Treating depression in Parkinson's patients

A group of scientists from the University of Kentucky College of Medicine and the Sanders-Brown Center on Aging has found interesting new information in a study on depression and neuropsychological function in Parkinson's ...

Impact glass stores biodata for millions of years

(Phys.org) —Bits of plant life encapsulated in molten glass by asteroid and comet impacts millions of years ago give geologists information about climate and life forms on the ancient Earth. Scientists ...

Airbnb rental site raises $450 mn

Online lodging listings website Airbnb inked a $450 million funding deal with investors led by TPG, a source close to the matter said Friday.